This is an open label Phase 2 clinical study of Zandelisib with Venetoclax (VEN) and Rituximab (R) in subjects with R/R CLL.~VEN and R will be administered per standard of care.~Subjects must have histologically confirmed relapsed/refractory CLL and received ≥1 lines of prior therapy~A total 42 subjects will be enrolled and treated with zandelisib in combination with VEN + R.
A Phase 2 study of Zandelisib with Venetoclax (VEN) and Rituximab (R) in subjects with Relapsed/Refractory CLL.